logo_basilea

About the Company

Basilea Pharmaceutica (SIX: BSLN.S) is a commercial stage biopharmaceutical company with two marketed anti-infective products and two early stage oncology assets. CRESEMBA is a potent antifungal with activity against multiple clinically relevant species that is approved in both the US and Europe. Basilea has a commercialization agreement with Astellas for the drug in the US. Zevtera, a broad-spectrum antibiotic, has been approved in over a dozen European countries for the treatment of community acquired and hospital acquired pneumonia. It has QIDP status and BARDA funding for a US Phase III program, which is expected to begin in the first half of 2017. BAL3833 is a kinase inhibitor indicated for melanoma and other small tumors that is currently being evaluated in a Phase I study for the treatment of refractory solid tumors. BAL101553 showed early signs of efficacy in Phase I/IIa study and an oral study is ongoing.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.


Recent Research